Natural remedies for anxiety disorders: potential use and clinical applications

Depression and Anxiety

Volumn 26, Issue 3, 2009, Pages 259-265

  Kinrys, Gustavo ^a,b   Coleman, Eliza ^a,b   Rothstein, Ethan ^a,b  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alternative medications; Alternative therapy; Anxiety; Anxiolytics; Natural remedies

Indexed keywords

DIAZEPAM; FLUVOXAMINE; HERBACEOUS AGENT; HYPERICIN; INOSITOL; KAVA; MELATONIN; OMEGA 3 FATTY ACID; OXAZEPAM; PASSIFLORA INCARNATA EXTRACT; S ADENOSYLMETHIONINE; VALERIAN;

ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG DOSE TITRATION; DRUG MECHANISM; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERICUM PERFORATUM; INSOMNIA; MANIA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; SOCIAL PHOBIA;

ANTI-ANXIETY AGENTS; ANTIOXIDANTS; ANXIETY DISORDERS; HUMANS; HYPERICUM; INOSITOL; KAVA; MELATONIN; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; PASSIFLORA; PHYTOTHERAPY; VALERIAN;

EID: 63849284109     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20460     Document Type: Article

References (47)

1. National Institutes of Health Office of Alternative Medicine. Clinical practice guidelines in complementary and alternative medicine. An analysis of opportunities and obstacles. Practice and policy guidelines panel. Arch Fam Med 1997;6:149-154.
2. Thiele B, Ploch M, Brink I. Modulation of cytokine expression by hypericum extract. Nevenheilkunde 1993;12:353-356.
3. Muller W, Rossol R. Effects of hypericum extract on the expression of serotonin receptors. Nervenheilkunde 1993;12: 357-358.
4. Teufel-Mayer R, SleitzJ. Effects of long-term administration of hypericum extracts on the affinity and density of the central sertonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsy- chiatry 1997;30:113-116.
5. Schulz V, Hänsel R, Blumenthal M, Tyler VE. Rational phytotherapy (5th ed.). Berlin, Heidelberg, New York: Springer; 2004.
6. Lawvere S, Mahoney MC. St. John's wort. Am Fam Physician 2005;72:2249-2254.
7. Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S54-S56.
8. Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000;20:568-574.
9. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355: 134-138.
10. Prost N, Tichadou L, Rodor F, Nguyen N, David JM, Jean- Pastor MJ. St. John's wort-venlafaxine interaction. Presse Med 200029:1285-1286.
11. Laakmann G, Schule C, Baghai T, Kieser M. St John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998;31(Suppl 1):54-59.
12. Schellenberg R, Sauer S, Dimpfel W. Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG. Pharmacopsychiatry 1998;31:44-53.
13. Orth HC, Rentel C, Schmidt PC. Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L. J Pharm Pharmacol 1999;51:193-200.
14. Kobak K, Taylor L, Futterer R, Warnder G. St. John's wort in Generalized Anxiety Disorder: three more case reports. J Clin Psychopharmacol 2003;23:531-532.
15. Kobak K, Taylor L, Warner G, Futterer R. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005;25:51-58.
16. Taylor L, Kobak K. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive compulsive disorder. J Clin Psychiatry 2000;61:575-578.
17. Kobak KA, Taylor LV, Bystritsky A, Kohlenberg CJ, Greist JH, Tucker P, Warner G, Futterer R, Vapnik T. St. John's wort versus placebo in obsessive-compulsive disorder: results from a double blind study. Int Clin Psychopharmacol 2005;20:299-304.
18. Davidson JRT, Connor KM. St. John's wort in generalized anxiety disorder: three case reports. J Clin Psychopharmacol 2001;21:635-636.
19. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994;116:469-474.
20. Yuan CS, Dey L, Wang A, Mehendale S, Xie JT, Aung HH, Ang- Lee MK. Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation. Planta Med 2002;68:1092-1096.
21. Gleitz J, Beile A, Peters T. (+/-)Kavain inhibits the veratridine-and KCl-induced increase in intracellular Ca2+ and glutamate- release of rat cerebrocortical synaptosomes. Neuropharmacology 1996;35:179-186.
22. Gleitz J, Friese J, Beile A, Ameri A, Peters T. Anticonvulsive action of (+/-)kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 1996;315:89-97.
23. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003;1:CD003383.
24. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS 1490 in patients with non-psychotic anxiety disorders. Phytother Res 2005;19:183-188.
25. Connor KM, Davidson JR, Churchill LE. Adverse-effect profile of kava. CNS Spectr 2001;6:848, 850-853.
26. Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol 2006;21:249-253.
27. Bradley PR, editor. British herbal compendium, Vol. 1. Bournemouth: British Herbal Medicine Association; 1992.
28. Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J Ethnopharmacol 2001;78:165-170.
29. Dhawan K, Kumar S, Sharma A. Suppression of alcohol-cessation-oriented hyper-anxiety by the benzoflavone moiety of Passiflora incarnata Linneaus in mice. J Ethnopharmacol 2002;81:239-244.
30. Dhawan K, Dhawan S, Chhabra S. Attenuation of benzodiaze- pine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. J Pharm Pharmaceut Sci 2003;6:215-222.
31. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khan M. Passionflower in the treatment of Generalized Anxiety Disorder: a pilot double-blind randomized controlled trial withoxazepam. JClin Pharm Ther 2001;26:363-367.
32. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharm 2001;21:335-339.
33. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152: 1084-1086.
34. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153: 1219-1221.
35. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol 1999;2:193-195.
36. Carey PD, Warwick J, Harvey BH, Stein DJ, Seedat S. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 2004;4:30.
37. Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 2004;98:353-358.
38. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5- HT5a receptor in vitro. Brain Res Mol Brain Res 2005;138:191-197.
39. Kohnen R, Oswald D. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry 1988;21:447-448.
40. Panijel M. Therapy of symptoms of anxiety. Therapiewoche 1985;41:4659-4668.
41. Zhdanova IV, Giorgetti M. Melatonin alters behavior and cAMP levels in nucleus accumbens induced by cocaine treatment. Brain Res 2002;956:323-331.
42. Zhdanova IV, Piotrovskaya VR. Melatonin reduces symptoms of acute nicotine withdrawal in humans. Pharm Biochem Behav 2000;67:131-135.
43. Green P, Hermesh H, Monselise A, Marom S, Presburger G, Weizman A. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol 2006;16:107-113.
44. Fux M, Benjamin J, Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 2004;38: 323-325.
45. Spillmann M, Fava M. S-adenosyl-methionine (ademethionine) in psychiatric disorders. CNS Drugs 1996;6:416-425.
46. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr2002;76:1158S-1161S.
47. Carney MWP, Chary TNK, Bottiglieri T. Switch mechanism in affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry 1987;150:724-725.